Elbrit Life Sciences to expand its domestic footprint with USD 3 million investments

Elbrit Life Sciences is now expanding its footprint in the domestic pharmaceutical industry. The company is presently in advanced talks with its parent investment firm, Capital Investments and a Qatar-based investment firm to raise USD 3 million. This major investment is aimed at expanding the company’s domestic footprint in the branded formulation business. Elbrit Life Sciences started its operations in 2014 and has since witnessed an impressive growth rate of more than 100 percent per annum. The company majorly operates in South India and has a sales force strength of 200 frontline sales representatives. It has 45 brands and 150 SKUs.

The company is currently not looking at any acquisitions and instead prefers to take the organic route to fuel further growth and is planning to use the additional funds to expand geographical footprint and to focus on nephrology, urology, gynecology, and oncology therapy segments. Moreover, the pharma company is in the process of upgrading its facilities to foray into export markets. Elbrit Life Sciences also aims to be amongst the top 150 pharmaceutical companies by the year 2020.